Life

Bushu Pharmaceuticals, Ltd., a major contract manufacturing company, is working to eliminate human error to ensure the integrity of test results data, and to promote reliable inspections and paperless operations.

Establish thorough quality assurance with state-of-the-art facilities and technologies to foster the future of medical products.

At Shionogi, the facility maintenance management system eHOZEN, the pr edecessor of eServ, has been used for about 10 years. However, due to the aging of servers and systems, they have begun considering renewing the system with the latest one. When considering this, suggestions from several vendors were received assuming that the system package safely migrates data assets accumulated on the current server and meets the following requirements:

The introduction of eServ has resulted in a centralized system of facility information. The reason for the loss of production opportunities has become clear, and it has become possible for all members to follow up the progress of the measures.

A critical requirement in biopharmaceutical development is the integration and automation of process equipment and analytical instruments used in the laboratory. Bioprocess labs with multiple lab-scale bioreactors often execute cultivation experiments in parallel for research or process development purposes.

As part of a collaboration between Securecell (Zurich, SW) and Yokogawa Life Science (Tokyo, Japan), this application note demonstrates the effective use of the Lucullus® Process Information Management System (Lucullus®) to assist in the control of three Advanced Control Bioreactor Systems (BR1000) to study glucose utilization of CHO cells for optimal monoclonal antibody productivity.

Exploring the technologies needed to achieve automatic control of cell culture processes.

Yokogawa Electric began offering the environmental monitoring system "OpreX Environmental Monitoring System" (hereinafter, OpreX EMS) for the pharmaceutical and medical device industries in October 2020. OpreX EMS, which was launched simultaneously domestically and overseas, is based on customers' needs, such as regulatory compliance, diversification of operational risks, and high usability. When asking the person in charge about the development history and features of the product, it was found that it is a new solution that meets the company's business vision.

Our approach is to leverage state-of-the-art technologies for real-time monitoring and predictive control that allow virtual environments where "digital twin" processes can provide distinct advantages.

Connecting MES and DCS in your pharma or biotech factory: Werum PAS-X MES and Yokogawa CENTUM VP

The Yokogawa business vision states that the company endeavors to achieve Net-zero emissions, ensure the Well-being of all, and make a transition to a Circular Economy by 2050. 

YOKOGAWA aspires to establish Smart GMP manufacturing facilities that provide consistent quality and supply while eliminating industrial waste, enhancing productivity and always using high-quality component parts and materials.

YOKOGAWA will contribute to technology evolution particularly in measurement and analytical tools to help build a world where researchers will increasingly focus on insightful interpretation of data, and advancing Life Science to benefit humanity.

YOKOGAWA creates autonomous operations with high-efficiency automation and optimization that allows growth with minimal deployment of manpower.

By adopting the environmental monitoring system, we were able to create an environment in the cell storage facility that allows for quality control, maintaining a high level of safety.

In this webinar, Professor Jonny Sexton discusses a pipeline, developed in the Sexton lab, for the quantitative high-throughput image-based screening of SARS-CoV-2 infection to identify potential antiviral mechanisms and allow selection of appropriate drug combinations to treat COVID-19. This webinar presents evidence that morphological profiling can robustly identify new potential therapeutics against SARS-CoV-2 infection as well as drugs that potentially worsen COVID-19 outcomes.